Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.64
5.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hubei Biocause Pharmaceutical Co Ltd
Long-Term Debt
Hubei Biocause Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
|
Long-Term Debt
¥5.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
China Life Insurance Co Ltd
SSE:601628
|
Long-Term Debt
¥14B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-15%
|
|
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
Long-Term Debt
¥1.1T
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
New China Life Insurance Company Ltd
SSE:601336
|
Long-Term Debt
¥31.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
45%
|
CAGR 10-Years
8%
|
|
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
Long-Term Debt
¥20.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hubei Biocause Pharmaceutical Co Ltd
Glance View
Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.
See Also
What is Hubei Biocause Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
5.6B
CNY
Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Long-Term Debt amounts to 5.6B CNY.
What is Hubei Biocause Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-2%
Over the last year, the Long-Term Debt growth was -21%. The average annual Long-Term Debt growth rates for Hubei Biocause Pharmaceutical Co Ltd have been -2% over the past three years .
You don't have any saved screeners yet
